KOSDAQCosmetics016100

Leaders Cosmetics

₩1,038▲ 2.37%2026-11-18 close
Market Cap
₩19.8B
Turnover
₩2,767,579
Volume
2.7K
Shares out.
19.1M
PER
—
PBR
—
EPS
-₩444
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Corrugated base; narrowing cosmetics losses is the test

Operating losses widened to KRW 7.09 billion in 2025 and then narrowed to KRW 541 million in the third quarter of 2026, but annual profitability has not yet turned.

  1. 1

    2025 revenue was KRW 68.3 billion and the operating loss was KRW 7.09 billion, with operating losses in each year from 2023 to 2025.

  2. 2

    Operating losses shrank every quarter from the first to the third quarter of 2026, at KRW 2.33 billion, KRW 1.46 billion and KRW 541 million.

  3. 3

    The 2025 revenue mix was 79.5% corrugated packaging and 20.5% cosmetics, so cosmetics growth is central to any recovery.

  4. 4

    The company announced cumulative sales of 200,000 units of its eye-cream product and entry into Japan and China.

  5. 5

    A March 2026 domestic exclusive sales license for the osteoarthritis drug E1K has become a variable for expansion into bio and healthcare.

02

Business structure

Leaders Cosmetics runs two main businesses: cosmetics manufacturing and sales, and corrugated paper sheets and boxes. Corrugated packaging accounted for 79.5% of 2025 consolidated revenue and cosmetics for 20.5%.

In won terms, the corrugated division generated KRW 54.34 billion and cosmetics KRW 13.97 billion, per segment figures compiled by a local rating agency's technology report.

The cosmetics business is built on product development rooted in the clinical experience of Leaders Skin Clinic, a cosmeceutical focus, and the company holds patents covering functional cosmetics such as nanoparticle skin-barrier technology.

Its flagship product, the PDRN+ 2% Flat Eye Back Cream, launched on CJ OliveYoung's home-shopping channel in February 2026 and has aired around 80 times across six major home-shopping channels. Overseas, the company describes itself as present in Japan, China, the United States and Thailand.

Corrugated packaging is supported by e-commerce-driven packaging demand and the replacement of styrofoam. Cosmetics faces market saturation, which weighed on the segment. In 2026 the company secured the domestic exclusive sales license for the osteoarthritis drug E1K, extending its business into bio and healthcare.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩18.9B-₩1.6B−8.5%
2025Q4₩11.6B-₩3.1B−26.6%
2026Q1₩17.2B-₩2.3B−13.5%
2026Q2₩20.6B-₩1.5B−7.1%
2026Q3₩19.5B-₩500M−2.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩86.7B₩500M-₩800M0.6%−1.8%83.5%
2023₩69.3B-₩4.3B₩200M−6.2%0.4%80.9%
2024₩73.5B-₩2.9B-₩3.2B−3.9%−8.7%99.8%
2025₩68.3B-₩7.1B-₩8.3B−10.4%−29.0%143.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue moved from KRW 86.7 billion in 2022 to KRW 69.3 billion in 2023 (down 20.1% year on year), KRW 73.5 billion in 2024 (up 6.1%) and KRW 68.3 billion in 2025 (down 7.1%). The largest year in 2022–2025 was 2022 and the smallest was 2025.

Operating profit of KRW 505 million in 2022 (margin 0.6%) turned into an operating loss of KRW 4.31 billion in 2023 (margin -6.2%). The loss narrowed to KRW 2.9 billion in 2024 (margin -3.9%) and then widened to KRW 7.09 billion in 2025 (margin -10.4%).

Operating losses were recorded in three years, from 2023 through 2025. The company attributed the 2025 loss widening mainly to lower sales and higher costs, and said the recognition of an impairment assessment on tangible and intangible assets affected the net loss.

Owner net income turned to a profit of KRW 173 million in 2023, then posted net losses of KRW 3.25 billion in 2024 and KRW 8.29 billion in 2025, two consecutive loss years.

The debt-to-equity ratio rose from 83.5% in 2022 to 143.0% in 2025, with total liabilities of KRW 41 billion against total equity of KRW 28.7 billion at end-2025. Operating cash flow went from KRW 3.2 billion in 2022 to -KRW 5.64 billion in 2023, KRW 71.51 million in 2024 and -KRW 3.52 billion in 2025.

Quarterly, the operating loss widened from KRW 1.61 billion in Q3 2025 to KRW 3.08 billion in Q4 2025, when revenue fell 38.5% quarter on quarter to KRW 11.6 billion.

Q1 2026 revenue was KRW 17.2 billion with an operating loss of KRW 2.33 billion, Q2 revenue KRW 20.6 billion with a loss of KRW 1.46 billion, and Q3 revenue KRW 19.5 billion with a loss of KRW 541 million; Q3 revenue rose 3.4% year on year. Owner net losses over the last four quarters totaled KRW 8.31 billion.

05

Industry analysis

The cosmetics market is described as growing on shifting purchasing patterns and an expanding distribution network.

Against that backdrop, Leaders Cosmetics' cosmetics division saw results worsen in the first half of 2026 as the market saturated and summer demand fell, according to an analysis by a market data provider. The corrugated division, by contrast, benefited from higher parcel volumes that widened packaging demand.

On home-shopping channels, PDRN ingredients have become a mainstream favorite for skin-elasticity care. Industry observers link the company's hit products to a combination of R&D capability and high-functionality ingredient formulation.

Competitively, its cosmetics business is a self-branded cosmeceutical model, which differs in scale and model from contract-manufacturing peers such as Cosmax and Kolmar Korea, and from large brand owners such as Amorepacific and LG H&H.

Corrugated demand is supported by e-commerce, but margins can move with paper and raw-material prices. Whether cosmetics market growth translates into company-wide revenue is a question for the segment revenue trend.

06

Outlook

The company said it will keep up growth in the second half of 2026 through upgrades to its basic skincare line and new product launches. The eye-cream product leads a PDRN+ lineup that is being built out with toners, ampoules, creams and gel masks.

A July 2026 technical report by a rating agency projected 2026 consolidated revenue of KRW 70 billion, split into KRW 55 billion from corrugated packaging and KRW 15 billion from cosmetics. This is an outside estimate, not company guidance.

Q1–Q3 2026 revenue totals KRW 57.3 billion, so reaching the KRW 70 billion projection would require roughly KRW 12.7 billion in Q4 revenue. The company signed a domestic exclusive sales license for E1K in March 2026.

E1K is in Phase 3 clinical trials, and a fixed technology fee of about KRW 100 billion was reported under the contract. How and when that fee is booked and collected will be visible in the periodic reports. In the same month, a counterparty agreed to acquire 765,067 shares, a 4.01% stake, in the company. Near-term checkpoints are execution of the new product plan and the quarterly trend in cosmetics revenue.

07

Valuation

PER
—
PBR
—
ROE
-20.0%
EPS
-₩444
BPS
—
Dividend per share
₩0

The P/E ratio cannot be calculated because the last four quarters show net losses. Dividend returns are low, so dividend-based metrics offer little help in gauging valuation. Market capitalization sits below total equity at end-2025 (KRW 28.7 billion), meaning shares trade at a discount to book value.

The price-to-book ratio was below 1x at end-2025. Whether that relationship persists depends on the pace of earnings recovery. Quarterly operating losses of KRW 2.33 billion, KRW 1.46 billion and KRW 541 million in 2026 point toward narrowing losses.

Share price swings have been large, and the stock was designated as a caution-listed issue in June and August 2026. A side-by-side comparison with listed peers on book-value multiples is the most direct factual check.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Strong response to new cosmetics products

The company reported three consecutive sell-outs on home-shopping broadcasts and cumulative sales above 200,000 units, while expanding its PDRN lineup with Japan and China entries. Bulls argue that a cosmetics recovery could widen the narrowing of operating losses.

Operating losses narrowing

Q3 2026 operating loss narrowed to KRW 541 million from KRW 3.08 billion in Q4 2025, and Q3 revenue rose 3.4% year on year. Bulls point to the quarter-by-quarter reduction in losses through 2026.

Bio and healthcare expansion option

The E1K license adds a third business axis beyond cosmetics and corrugated packaging, with a fixed fee reported at about KRW 100 billion. Bulls argue that Phase 3 results and commercialization timing could reshape the business mix.

09

Bear factors

Cumulative losses and debt burden

The debt-to-equity ratio stood at 143.0% at end-2025, with total liabilities of KRW 41 billion. Net losses attributable to owners have continued over the last four quarters, and operating cash flow was -KRW 3.52 billion in 2025, which bears cite as a constraint.

Slowing demand in cosmetics

Consolidated operating losses in the first half of 2026 rose 58.2% year on year as market saturation and weaker summer demand weighed on cosmetics. Bears question whether the KRW 15 billion cosmetics projection for 2026 will be achieved.

E1K trial uncertainty and governance factors

E1K is still in Phase 3, so its contract value depends on trial results. The largest shareholder has pledged about 2.54 million shares, and the company has said the pledges could lead to a change of largest shareholder if enforced.

10

Risk factors

Governance and share pledges

The largest shareholder holds 13.6%, and a full enforcement of pledges would reduce that to about 0.3%. The March 2026 shareholder meeting re-elected two executive directors, with three of five board members independent. Any change in control is a continuity variable.

Financial capacity

Total equity was KRW 28.7 billion and total liabilities KRW 41 billion at end-2025. The 2025 net loss reflected impairment assessments on tangible and intangible assets, and first-half 2026 losses widened, so equity headroom and working-capital flows matter.

Share price volatility and contract uncertainty

The exchange designated the stock as a caution-listed issue in June and August 2026 due to concentrated trading by a small number of accounts. A stock option grant approved by the board was also ratified at the March 2026 meeting. The accounting treatment of the E1K fee remains a periodic-report item.

11

What to watch next

  1. By end of December 2026

    Whether planned upgrades to the basic line and new product launches are executed. The cosmetics revenue trend is the key variable for an earnings turn.

  2. January 31, 2027

    The end of the tax-related pledge period for the largest shareholder. Filings will show whether the pledge structure changes.

  3. End of March 2027

    The 2026 annual report deadline. It will show full-year 2026 operating margin, cosmetics segment profit and the accounting treatment of the E1K fee.

  4. Mid-May 2027

    The Q1 2027 quarterly report. Investors can check whether market saturation and seasonal demand effects show in year-on-year comparisons.

  5. Date not yet set

    Phase 3 results and commercialization timing for E1K. The outcome could change the weight of the bio and healthcare business and the contract's value.

12

Overall view

Leaders Cosmetics has a structure in which corrugated packaging carries most of the revenue and cosmetics faces a profitability challenge. The 2025 report showed revenue of KRW 68.3 billion and an operating loss of KRW 7.09 billion, with losses from 2023 through 2025.

Quarterly operating losses in 2026 of KRW 2.33 billion, KRW 1.46 billion and KRW 541 million show the gap narrowing. However, first-half 2026 consolidated operating losses rose 58.2% year on year, and cosmetics was hit by market saturation and weaker summer demand.

Bull factors include eye-cream home-shopping sales, overseas entry and the E1K license. Bear factors include a debt-to-equity ratio of 143.0%, owner net losses of KRW 8.31 billion over the last four quarters, share pledges by the largest shareholder and share price volatility.

The company's overall trajectory can be gauged by quarterly results and whether the KRW 70 billion external projection is reached. The next checkpoints are the full-year results in the 2026 annual report and the accounting treatment of the E1K contract.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. comp.fnguide.com
  3. m.jobkorea.co.kr
  4. beautynury.com
  5. m.news.nate.com
  6. beautynury.com
  7. saramin.co.kr
  8. catch.co.kr
  9. newspim.com
  10. news.nate.com
  11. m.news.nate.com
  12. m.news.nate.com
  13. seoul.co.kr
  14. topstarnews.net
  15. m.news.nate.com
  16. topstarnews.net
  17. topstarnews.net
  18. seoul.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis